Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1

Biochemical Pharmacology

Volumn 81, Issue 1, 2011, Pages 82-90

  Damaraju, Vijaya L ^a   Smith, Kyla M ^a   Mowles, Delores ^a   Nowak, Ireneusz ^b   Karpinski, Edward ^a   Young, James D ^a   Robins, Morris J ^b   Cass, Carol E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Brigham Young University   (United States)

Author keywords

Concentrative; Gemcitabine; Inhibitors; Nucleoside transport; Pyrimidine nucleosides

Indexed keywords

2' DEOXYNUCLEOSIDE; ADENOSINE; HUMAN CONCENTRATIVE NUCLEOSIDE TRANSPORTER; HUMAN CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; HUMAN CONCENTRATIVE NUCLEOSIDE TRANSPORTER 2; HUMAN CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; NUCLEOSIDE TRANSPORTER; PYRIMIDINE NUCLEOSIDE DERIVATIVE; RIBONUCLEOSIDE; THIENOPYRIMIDINE 2' DEOXYNUCLEOSIDE; UNCLASSIFIED DRUG; URIDINE;

ACTIVE TRANSPORT; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; OOCYTE; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; XENOPUS LAEVIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPROTECTION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA; MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; OOCYTES; PYRIMIDINE NUCLEOSIDES; SACCHAROMYCES CEREVISIAE; XENOPUS LAEVIS;

EID: 78549288458     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.09.009     Document Type: Article

References (42)

1. King A.E., Ackley M.A., Cass C.E., Young J.D., Baldwin S.A. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 2006, 27:416-425.
2. Molina-Arcas M., Trigueros-Motos L., Casado F.J., Pastor-Anglada M. Physiological and pharmacological roles of nucleoside transporter proteins. Nucleos Nucleot Nucleic Acids 2008, 27:769-778.
3. Zhang J., Visser F., King K.M., Baldwin S.A., Young J.D., Cass C.E. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 2007, 26:85-110.
4. Baldwin S.A., Beal P.R., Yao S.Y., King A.E., Cass C.E., Young J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004, 447:735-743.
5. Baldwin S.A., Yao S.Y., Hyde R.J., Ng A.M., Foppolo S., Barnes K., et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005, 280:15880-15887.
6. Griffiths M., Beaumont N., Yao S.Y., Sundaram M., Boumah C.E., Davies A., et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 1997, 3:89-93.
7. Griffiths M., Yao S.Y., Abidi F., Phillips S.E., Cass C.E., Young J.D., et al. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 1997, 328(Pt 3):739-743.
8. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001, 276:2914-2927.
9. +-nucleoside cotransporter (hCNT1). Am J Physiol 1997, 272:C707-C714.
10. +/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 1998, 15:203-211.
11. Huang Q.Q., Yao S.Y., Ritzel M.W., Paterson A.R., Cass C.E., Young J.D. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J Biol Chem 1994, 269:17757-17760.
12. Mackey J.R., Yao S.Y., Smith K.M., Karpinski E., Baldwin S.A., Cass C.E., et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999, 91:1876-1881.
13. Ngo L.Y., Patil S.D., Unadkat J.D. Ontogenic and longitudinal activity of Na(+)-nucleoside transporters in the human intestine. Am J Physiol Gastrointest Liver Physiol 2001, 280:G475-G481.
14. Cass C.E., Gaudette L.A., Paterson A.R. Mediated transport of nucleosides in human erythrocytes. Specific binding of the inhibitor nitrobenzylthioinosine to nucleoside transport sites in the erythrocyte membrane. Biochim Biophys Acta 1974, 345:1-10.
15. Pickard M.A., Brown R.R., Paul B., Paterson A.R. Binding of the nucleoside transport inhibitor 4-nitrobenzylthioinosine to erythrocyte membranes. Can J Biochem 1973, 51:666-672.
16. Gupte A., Buolamwini J.K. Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett 2009, 19:917-921.
17. Wang C., Pimple S., Buolamwini J.K. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. Biochem Pharmacol 2010, 79:307-320.
18. Robins M.J., Barr P.J. Efficient conversion of 5-iodo to 6-alkynyl and derived 5-substituted uracil bases and nucleosides. J Org Chem 1983, 48:1854-1862.
19. Robins M.J., Barr P.J., Giziewicz J. Nucleic acid related compounds. Smooth and high-yield iodination and chlorination at C-5 of uracil bases and p-toluyl-protected nucleosides. Can J Chem 1982, 60:554-557.
20. Zhang J., Smith K.M., Tackaberry T., Visser F., Robins M.J., Nielsen L.P., et al. Uridine binding and transportability determinants of human concentrative nucleoside transporters. Mol Pharmacol 2005, 68:830-839.
21. Zhang J., Visser F., Vickers M.F., Lang T., Robins M.J., Nielsen L.P., et al. Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Mol Pharmacol 2003, 64:1512-1520.
22. Vickers M.F., Yao S.Y., Baldwin S.A., Young J.D., Cass C.E. Nucleoside transporter proteins of Saccharomyces cerevisiae. Demonstration of a transporter (FUI1) with high uridine selectivity in plasma membranes and a transporter (FUN26) with broad nucleoside selectivity in intracellular membranes. J Biol Chem 2000, 275:25931-25938.
23. Vickers M.F., Kumar R., Visser F., Zhang J., Charania J., Raborn R.T., et al. Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae. Biochem Cell Biol 2002, 80:639-644.
24. Visser F., Vickers M.F., Ng A.M., Baldwin S.A., Young J.D., Cass C.E. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem 2002, 277:395-401.
25. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
26. +-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J Physiol 2004, 558:807-823.
27. Ullman B., Coons T., Rockwell S., McCartan K. Genetic analysis of 2',3'-dideoxycytidine incorporation into cultured human T lymphoblasts. J Biol Chem 1988, 263:12391-12396.
28. Lang T.T., Young J.D., Cass C.E. Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Mol Pharmacol 2004, 65:925-933.
29. Boleti H., Coe I.R., Baldwin S.A., Young J.D., Cass C.E. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology 1997, 36:1167-1179.
30. Damaraju V.L., Visser F., Zhang J., Mowles D., Ng A.M., Young J.D., et al. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside. Mol Pharmacol 2005, 67:273-279.
31. Yao S.Y., Ng A.M., Ritzel M.W., Gati W.P., Cass C.E., Young J.D. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes. Mol Pharmacol 1996, 50:1529-1535.
32. Wright A.M., Gati W.P., Paterson A.R. Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia 2000, 14:52-60.
33. Damaraju V.L., Damaraju S., Young J.D., Baldwin S.A., Mackey J., Sawyer M.B., et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003, 22:7524-7536.
34. Gloeckner-Hofmann K., Guillen-Gomez E., Schmidtgen C., Porstmann R., Ziegler R., Stoss O., et al. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 2006, 70:238-244.
35. Mackey J.R., Galmarini C.M., Graham K.A., Joy A.A., Delmer A., Dabbagh L., et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 2005, 105:767-774.
36. Marechal R., Mackey J.R., Lai R., Demetter P., Peeters M., Polus M., et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009, 15:2913-2919.
37. Buolamwini J.K. Nucleoside transporter inhibitors: structure-activity relationships and potential therapeutic applications. Curr Med Chem 1997, 4:35-66.
38. Kikuchi N., Nonaka Y., Tatani K., Hiratochi M., Kuramochi Y., Isaji M., et al. Preparation of ribofuranoside compounds having benzimidazole moiety as CNT2 inhibitors. PCT Int Appl 2005, 141.
39. Nonaka Y, Tatani K, Hiratochi M, Kuramochi Y, Isaji M. Preparation of 5'-modified nucleoside derivatives as CNT-2-inhibitors. Patent number WO 2004101593; 2004, USA.
40. Tatani KNY, Kikuchi N. Preparation of purine nucleoside derivatives modified in 8-position as inhibitors of concentrative nucleoside transporter 2. Patent number WO2006030803; 2006.
41. Wang C., Pimple S., Buolamwini J.K. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. Biochem Pharmacol 2010, 79(3):307-320.
42. Zhang J., Sun X., Smith K.M., Visser F., Carpenter P., Barron G., et al. Studies of nucleoside transporters using novel autofluorescent nucleoside probes. Biochemistry 2006, 45:1087-1098.